Alexander Starodub
About
Alexander Starodub is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Alexander Starodub has authored 109 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Alexander Starodub's work include HER2/EGFR in Cancer Research (26 papers), Colorectal Cancer Treatments and Studies (19 papers) and Peptidase Inhibition and Analysis (16 papers). Alexander Starodub is often cited by papers focused on HER2/EGFR in Cancer Research (26 papers), Colorectal Cancer Treatments and Studies (19 papers) and Peptidase Inhibition and Analysis (16 papers). Alexander Starodub collaborates with scholars based in United States, Canada and United Kingdom. Alexander Starodub's co-authors include David M. Goldenberg, William A. Wegener, Robert M. Sharkey, Michael J. Guarino, Serengulam V. Govindan, Pius Maliakal, Allyson J. Ocean, Manish A. Shah, Vincent J. Picozzi and Linda T. Vahdat and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Alexander Starodub
105 papers receiving 1.6k citations
Peers
Alexander Starodub
Michael J. Guarino United States
Ron Yu United States
Arne Scholz Germany
Hong Ge China
Anthony Kong United Kingdom
Catherine Mitchell Australia
Akihiko Shimomura Japan
Vijayakrishna K. Gadi United States
Michael J. Baine United States
Joyce Sanders Netherlands
Citations per year, relative to Alexander Starodub Alexander Starodub (= 1×)
peers
Michael J. Guarino
Countries citing papers authored by Alexander Starodub
Since
Specialization
Citations
This map shows the geographic impact of Alexander Starodub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Starodub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Starodub more than expected).
Fields of papers citing papers by Alexander Starodub
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alexander Starodub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Starodub. The network helps show where Alexander Starodub may publish in the future.
Co-authorship network of co-authors of Alexander Starodub
This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Starodub. A scholar is included among the top collaborators of Alexander Starodub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Starodub. Alexander Starodub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Spira, Alexander I., Kyriakos P. Papadopoulos, Daewon Kim, et al.. (2025). Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.. Journal of Clinical Oncology. 43(4_suppl). 724–724.
2.
Hecht, J. Randolph, Alexander I. Spira, Anthony V. Nguyen, et al.. (2025). A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).. Journal of Clinical Oncology. 43(4_suppl).
3.
Garrido‐Laguna, Ignacio, Brian M. Wolpin, Wungki Park, et al.. (2025). Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 43(4_suppl). 722–722.
4.
Starodub, Alexander, Sung‐Bae Kim, Diwakar Davar, et al.. (2024). TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.. Journal of Clinical Oncology. 42(16_suppl). 2601–2601.
5.
Park, Wungki, Jian Zhang, Farshid Dayyani, et al.. (2024). Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3002–3002.
6.
Papadopoulos, K., Apurvasena Parikh, Alexander Starodub, et al.. (2024). 502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. European Journal of Cancer. 211. 114980–114980.
7.
Gaillard, Stéphanie, Alexander Starodub, Bert H. O’Neil, et al.. (2024). A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS3181–TPS3181.
8.
Arbour, Kathryn C., Salman R. Punekar, Ignacio Garrido‐Laguna, et al.. (2023). 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S458–S458.
9.
Starodub, Alexander, S-B. Kim, Diwakar Davar, et al.. (2023). 1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy. Annals of Oncology. 34. S628–S628.
10.
Aggarwal, Rahul, Alexander Starodub, Brian D. Koh, et al.. (2022). Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(18). 3979–3989.
11.
Shah, Manish A., Alexander Starodub, Sunil Sharma, et al.. (2018). Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clinical Cancer Research. 24(16). 3829–3837.
12.
Heist, Rebecca S., Michael J. Guarino, Gregory A. Masters, et al.. (2017). Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Journal of Clinical Oncology. 35(24). 2790–2797.
13.
Bekaii‐Saab, Tanios, Alexander Starodub, Bassel F. El‐Rayes, et al.. (2017). A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts). Annals of Oncology. 28. iii150–iii150.
14.
Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. iii150–iii151.
15.
Sachdev, Jasgit C., et al.. (2016). A phase 1 dose-escalation study of the folic acid-tubulysin small molecule drug conjugate (SMDC) folate-tubulysin EC1456 in advanced cancer patients.. Journal of Clinical Oncology. 34(15_suppl). 2585–2585.
16.
Starodub, Alexander, Allyson J. Ocean, Manish A. Shah, et al.. (2015). First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical Cancer Research. 21(17). 3870–3878.
17.
Strickler, John H., Shannon J. McCall, Andrew B. Nixon, et al.. (2013). Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investigational New Drugs. 32(2). 330–339.
18.
Morse, Michael A., Lee Langer, Alexander Starodub, et al.. (2007). Current Immunotherapeutic Strategies in Colon Cancer. Surgical Oncology Clinics of North America. 16(4). 873–900.
19.
Ivanov, V. V., et al.. (1996). Investigation of the generation of high-energy electrons in a laser plasma. JETP. 82(4). 677–682.
20.
Bychenkov, V. Yu., О. Н. Крохин, A. A. Rupasov, et al.. (1977). Ultrahigh speed diagnostics of the parameters of laser plasma corona. 26. 364–367.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michael J. Guarino Breakdown of academic impact, for papers by Ron Yu Breakdown of academic impact, for papers by Arne Scholz Breakdown of academic impact, for papers by Hong Ge Breakdown of academic impact, for papers by Anthony Kong Breakdown of academic impact, for papers by Catherine Mitchell Breakdown of academic impact, for papers by Akihiko Shimomura Breakdown of academic impact, for papers by Vijayakrishna K. Gadi Breakdown of academic impact, for papers by Michael J. Baine Breakdown of academic impact, for papers by Joyce Sanders